NSG 6005 Pharm Weeks 1-3 (from
Operation FNP Class 11) 2025/2026
Exam Questions and Answers | A+ Score
Assured
Genetic polymorphisms account for differences in metabolism, including:
1. Poor metabolizers, who lack a working enzyme
2. Intermediate metabolizers, who have one working, wild-type allele and
one mutant allele
3. Extensive metabolizers, with two normally functioning alleles
4. All of the above - 🧠 ANSWER ✔✔4. All of the above
Up to 21% of Asians are ultra-rapid 2D6 metabolizers, leading to:
COPYRIGHT©PROFFKERRYMARTIN 2025/2026. YEAR PUBLISHED 2025. COMPANY REGISTRATION NUMBER: 619652435. TERMS OF USE.
1
PRIVACY STATEMENT. ALL RIGHTS RESERVED
,1. A need to monitor drugs metabolized by 2D6 for toxicity
2. Increased dosages needed of drugs metabolized by 2D6, such as the
selective serotonin reuptake inhibitors
3. Decreased conversion of codeine to morphine by CYP 2D6
4. The need for lowered dosages of drugs, such as beta blockers - 🧠
ANSWER ✔✔2. Increased dosages needed of drugs metabolized by 2D6,
such as the selective serotonin reuptake inhibitors
Rifampin is a nonspecific CYP450 inducer that may:
1. Lead to toxic levels of rifampin and must be monitored closely
2. Cause toxic levels of drugs, such as oral contraceptives, when
coadministered
COPYRIGHT©PROFFKERRYMARTIN 2025/2026. YEAR PUBLISHED 2025. COMPANY REGISTRATION NUMBER: 619652435. TERMS OF USE.
2
PRIVACY STATEMENT. ALL RIGHTS RESERVED
,3. Induce the metabolism of drugs, such as oral contraceptives, leading to
therapeutic failure
4. Cause nonspecific changes in drug metabolism - 🧠 ANSWER ✔✔3.
Induce the metabolism of drugs, such as oral contraceptives, leading to
therapeutic failure
Inhibition of P-glycoprotein by a drug such as quinidine may lead to:
1. Decreased therapeutic levels of quinidine
2. Increased therapeutic levels of quinidine
3. Decreased levels of a coadministered drug, such as digoxin, that
requires P-
glycoprotein for absorption and elimination
COPYRIGHT©PROFFKERRYMARTIN 2025/2026. YEAR PUBLISHED 2025. COMPANY REGISTRATION NUMBER: 619652435. TERMS OF USE.
3
PRIVACY STATEMENT. ALL RIGHTS RESERVED
, 4. Increased levels of a coadministered drug, such as digoxin, that requires
P-
glycoprotein for absorption and elimination - 🧠 ANSWER ✔✔4. Increased
levels of a coadministered drug, such as digoxin, that requires P-
glycoprotein for absorption and elimination
Warfarin resistance may be seen in patients with VCORC1 mutation,
leading to:
1. Toxic levels of warfarin building up
2. Decreased response to warfarin
3. Increased risk for significant drug interactions with warfarin
4. Less risk of drug interactions with warfarin - 🧠 ANSWER ✔✔2.
Decreased response to warfarin
COPYRIGHT©PROFFKERRYMARTIN 2025/2026. YEAR PUBLISHED 2025. COMPANY REGISTRATION NUMBER: 619652435. TERMS OF USE.
4
PRIVACY STATEMENT. ALL RIGHTS RESERVED
Operation FNP Class 11) 2025/2026
Exam Questions and Answers | A+ Score
Assured
Genetic polymorphisms account for differences in metabolism, including:
1. Poor metabolizers, who lack a working enzyme
2. Intermediate metabolizers, who have one working, wild-type allele and
one mutant allele
3. Extensive metabolizers, with two normally functioning alleles
4. All of the above - 🧠 ANSWER ✔✔4. All of the above
Up to 21% of Asians are ultra-rapid 2D6 metabolizers, leading to:
COPYRIGHT©PROFFKERRYMARTIN 2025/2026. YEAR PUBLISHED 2025. COMPANY REGISTRATION NUMBER: 619652435. TERMS OF USE.
1
PRIVACY STATEMENT. ALL RIGHTS RESERVED
,1. A need to monitor drugs metabolized by 2D6 for toxicity
2. Increased dosages needed of drugs metabolized by 2D6, such as the
selective serotonin reuptake inhibitors
3. Decreased conversion of codeine to morphine by CYP 2D6
4. The need for lowered dosages of drugs, such as beta blockers - 🧠
ANSWER ✔✔2. Increased dosages needed of drugs metabolized by 2D6,
such as the selective serotonin reuptake inhibitors
Rifampin is a nonspecific CYP450 inducer that may:
1. Lead to toxic levels of rifampin and must be monitored closely
2. Cause toxic levels of drugs, such as oral contraceptives, when
coadministered
COPYRIGHT©PROFFKERRYMARTIN 2025/2026. YEAR PUBLISHED 2025. COMPANY REGISTRATION NUMBER: 619652435. TERMS OF USE.
2
PRIVACY STATEMENT. ALL RIGHTS RESERVED
,3. Induce the metabolism of drugs, such as oral contraceptives, leading to
therapeutic failure
4. Cause nonspecific changes in drug metabolism - 🧠 ANSWER ✔✔3.
Induce the metabolism of drugs, such as oral contraceptives, leading to
therapeutic failure
Inhibition of P-glycoprotein by a drug such as quinidine may lead to:
1. Decreased therapeutic levels of quinidine
2. Increased therapeutic levels of quinidine
3. Decreased levels of a coadministered drug, such as digoxin, that
requires P-
glycoprotein for absorption and elimination
COPYRIGHT©PROFFKERRYMARTIN 2025/2026. YEAR PUBLISHED 2025. COMPANY REGISTRATION NUMBER: 619652435. TERMS OF USE.
3
PRIVACY STATEMENT. ALL RIGHTS RESERVED
, 4. Increased levels of a coadministered drug, such as digoxin, that requires
P-
glycoprotein for absorption and elimination - 🧠 ANSWER ✔✔4. Increased
levels of a coadministered drug, such as digoxin, that requires P-
glycoprotein for absorption and elimination
Warfarin resistance may be seen in patients with VCORC1 mutation,
leading to:
1. Toxic levels of warfarin building up
2. Decreased response to warfarin
3. Increased risk for significant drug interactions with warfarin
4. Less risk of drug interactions with warfarin - 🧠 ANSWER ✔✔2.
Decreased response to warfarin
COPYRIGHT©PROFFKERRYMARTIN 2025/2026. YEAR PUBLISHED 2025. COMPANY REGISTRATION NUMBER: 619652435. TERMS OF USE.
4
PRIVACY STATEMENT. ALL RIGHTS RESERVED
